Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes
Status:
Enrolling by invitation
Trial end date:
2024-01-15
Target enrollment:
Participant gender:
Summary
With increasing age and health issues associated with aging, many systemic cellular and
structural changes are known to occur. The intent of this trial is to determine the safety
and efficacy of delivery of autologous cellular stromal vascular fraction (cSVF) to improve
the quality of life and functional health.
Isolation and concentration of cSVF will be documented.
To acquire autologous cSVF, a 10+ teaspoon volume of subdermal adipose (fat) tissue and
stroma is removed from the trunk or upper thigh area. Using a closed system with enzymatic
digestion to isolate and concentrate these cells, is followed with returning these cSVF
elements only via 500 cc Normal Saline delivered via peripheral vein (IV).
Documentation of cellular numbers and flow cytometer viability testing is to be correlated
with clinical outcomes as reported by patients and standardized Quality of Life (QoL) form
tracking